Granules India (532482) Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 532482 from our risk checks.
532482 Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Granules India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹881.15 |
| 52 Week High | ₹879.00 |
| 52 Week Low | ₹433.00 |
| Beta | 0.062 |
| 1 Month Change | 15.19% |
| 3 Month Change | 39.44% |
| 1 Year Change | 85.86% |
| 3 Year Change | 191.43% |
| 5 Year Change | 137.92% |
| Change since IPO | 28,790.16% |
Recent News & Updates
Narrative Update • Jul 08
532482: Future Margins And Dividend Policy Will Shape Fair Value
The analyst fair value estimate for Granules India has been revised from ₹856 to ₹931, with analysts pointing to updated assumptions related to slightly higher revenue growth, profit margins and future P/E expectations. What's in the News Granules India board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to discuss a potential final dividend for FY 2025-26.
Narrative Update • Jun 11
532482: Fair Outlook Will Hinge On Upcoming FY 2025-26 Results And Dividend
Analysts have nudged their price target for Granules India higher to about ₹786 from roughly ₹698, citing updated assumptions that reflect adjusted revenue growth, profit margin expectations, discount rate inputs, and a revised future P/E multiple. What's in the News A board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any.Narrative Update • May 28
532482: Fair Value Will Depend On Margins And Dividend Sustainability
Analysts have lifted their price target on Granules India from ₹799 to ₹856, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News The board meeting is scheduled for April 29, 2026 to consider and approve audited financial results for Q4 and the full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any (Key Developments).Recent updates
Narrative Update • Jul 08
532482: Future Margins And Dividend Policy Will Shape Fair Value
The analyst fair value estimate for Granules India has been revised from ₹856 to ₹931, with analysts pointing to updated assumptions related to slightly higher revenue growth, profit margins and future P/E expectations. What's in the News Granules India board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to discuss a potential final dividend for FY 2025-26.Narrative Update • Jun 11
532482: Fair Outlook Will Hinge On Upcoming FY 2025-26 Results And Dividend
Analysts have nudged their price target for Granules India higher to about ₹786 from roughly ₹698, citing updated assumptions that reflect adjusted revenue growth, profit margin expectations, discount rate inputs, and a revised future P/E multiple. What's in the News A board meeting is scheduled for April 29, 2026, to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any.Narrative Update • May 28
532482: Fair Value Will Depend On Margins And Dividend Sustainability
Analysts have lifted their price target on Granules India from ₹799 to ₹856, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News The board meeting is scheduled for April 29, 2026 to consider and approve audited financial results for Q4 and the full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any (Key Developments).Narrative Update • May 01
532482: Fair Outlook Will Depend On Upcoming Results And Dividend Decision
Analysts have nudged their price target for Granules India up from about ₹678 to about ₹698, citing updated assumptions that reflect slightly higher projected revenue growth, profit margins, and a modestly adjusted future P/E multiple. What's in the News Board meeting scheduled for April 29, 2026 to consider and approve audited financial results for Q4 and the full year ended March 31, 2026, along with a potential final dividend recommendation for FY 2025-26 (company announcement).Narrative Update • Apr 17
532482: Fair Outlook Will Rely On Upcoming Results And Capital Deployment
Analysts have lifted their fair value estimate for Granules India from about ₹647 to roughly ₹678, citing updated assumptions around long term revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for April 29, 2026 to consider and approve audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any (Key Developments).Narrative Update • Apr 03
532482: Higher Fair Value Will Rely On Sustained Margin Improvement
Analysts have raised their price target on Granules India from ₹700.00 to about ₹799.28, reflecting updated views on fair value, discount rate assumptions, revenue growth and profit margin expectations, along with a lower future P/E multiple. What's in the News Granules India closed a private placement transaction on February 23, 2026, indicating recent activity in its capital raising plans (Key Developments).Narrative Update • Mar 20
532482: Capital Raise Through Convertible Warrants Will Support Future Earnings Upside Potential
Analysts have inched up their price target on Granules India from about ₹641 to around ₹647, reflecting updated assumptions that combine a slightly lower discount rate with higher projected revenue growth, improved profit margins and a more modest future P/E multiple. What's in the News The board of directors approved plans to raise a total of INR 17,625.0 million through a mix of convertible warrants and fresh equity, including up to 25.0 million convertible warrants at INR 585 each and up to 5,128,000 fully paid equity shares at INR 585 per share to selected non promoter investors (Key Developments).
Narrative Update • Mar 05
532482: Preferential Fundraising And Warrants Will Shape A Steady Outlook
Analysts have kept their fair value estimate for Granules India steady at ₹588. They have fine tuned their underlying assumptions around revenue growth, profit margins and future P/E to reflect updated expectations, without changing the overall price target.Narrative Update • Feb 19
532482: Fundraising Plans And Research Centres Will Shape A Balanced Outlook
Analysts have kept their fair value estimate for Granules India steady at ₹588, with only minor model tweaks to revenue growth, profit margin and future P/E assumptions informing this unchanged price target. What's in the News Board meeting scheduled on January 23, 2026 to consider and approve unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Feb 05
532482: Future Fundraising And R&D Initiatives Will Shape A Fair Outlook
Analysts have lifted their fair value estimate for Granules India from ₹480.00 to ₹588.00, citing slightly adjusted assumptions on the discount rate, revenue growth, profit margins and future P/E ratio to support the higher price target. What's in the News The board has approved proposals to raise a total of ₹17,625.0m through preferential issuance of convertible warrants and equity shares.Narrative Update • Jan 22
532482: Fundraising Through Convertible Warrants Will Support Earnings Upside Potential
Analysts have maintained their fair value estimate for Granules India at ₹640.71 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E that reflect a consistent view of the company’s long-term earnings potential. What's in the News A board meeting is scheduled on January 23, 2026 to consider and approve unaudited financial results for the third quarter and nine months ended December 31, 2025.Narrative Update • Jan 07
532482: Fundraising Plans And US Compliance Outlook Will Shape Balanced Future
Analysts have nudged up their fair value estimate for Granules India from ₹632.14 to ₹640.71 per share, reflecting refreshed assumptions on long term revenue growth, profit margin stability, and a slightly higher future P/E multiple in their models. What's in the News The board has approved plans to raise a total of ₹17,625.0 million via a preferential issuance of up to 2.5 crore convertible warrants and additional equity shares at ₹585 each.Narrative Update • Dec 14
532482: Upcoming German Acquisition And US Compliance Will Shape Balanced Outlook
Analysts have modestly reaffirmed their stance on Granules India, keeping the fair value estimate steady at ₹632.14 per share. They continue to forecast solid mid teens revenue growth and stable profit margins, supported by consistent execution and unchanged valuation multiples.Narrative Update • Nov 28
532482: Upcoming Board Decision On German Acquisition Will Drive Future Performance
Analysts have increased their price target for Granules India from ₹604.29 to ₹632.14, citing improved revenue growth forecasts. These forecasts are considered significant enough to offset a slight reduction in projected profit margins.Narrative Update • Nov 14
532482: Upcoming Regulatory Milestone And Profitability Outlook Will Shape Performance
Analysts have raised their price target for Granules India from ₹573.71 to ₹604.29. They cited improved profitability forecasts, even though revenue growth expectations are slightly lower.Narrative Update • Aug 27
FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity
The slight downward revision in Granules India’s consensus price target to ₹573.71 reflects marginally lower future P/E and revenue growth forecasts. What's in the News Dr. Kandiraju Venkata Sitaram Rao will resign as CEO of Granules India, effective at the close of business on July 31, 2025.
New Narrative • Feb 17
New Genome Valley Facility Will Increase Production Capacity To 10 Billion Doses
Strategic focus on expanding high-growth segments is expected to drive future revenue and enhance earnings stability through improved product approvals.Shareholder Returns
| 532482 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 6.6% | 0.9% | -1.1% |
| 1Y | 85.9% | 12.6% | -3.2% |
Return vs Industry: 532482 exceeded the Indian Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: 532482 exceeded the Indian Market which returned -3.2% over the past year.
Price Volatility
| 532482 volatility | |
|---|---|
| 532482 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: 532482 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532482's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 4,066 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions.
Granules India Limited Fundamentals Summary
| 532482 fundamental statistics | |
|---|---|
| Market cap | ₹212.58b |
| Earnings (TTM) | ₹5.95b |
| Revenue (TTM) | ₹53.66b |
36.7x
P/E Ratio4.1x
P/S RatioIs 532482 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532482 income statement (TTM) | |
|---|---|
| Revenue | ₹53.66b |
| Cost of Revenue | ₹18.76b |
| Gross Profit | ₹34.90b |
| Other Expenses | ₹28.95b |
| Earnings | ₹5.95b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.01 |
| Gross Margin | 65.04% |
| Net Profit Margin | 11.09% |
| Debt/Equity Ratio | 26.3% |
How did 532482 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield7%
Payout RatioDoes 532482 pay a reliable dividends?
See 532482 dividend history and benchmarks| Granules India dividend dates | |
|---|---|
| Ex Dividend Date | Jul 30 2026 |
| Dividend Pay Date | Sep 05 2026 |
| Days until Ex dividend | 20 days |
| Days until Dividend pay date | 57 days |
Does 532482 pay a reliable dividends?
See 532482 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 12:22 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Granules India Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| Cyndrella Carvalho | Centrum Broking Limited |
| Rashmi Sancheti Shetty | CGS International |